UNRESECTABLE HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA

Clinical trials for UNRESECTABLE HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA explained in plain language.

Never miss a new study

Get alerted when new UNRESECTABLE HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA trials appear

Sign up with your email to follow new studies for UNRESECTABLE HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New combo attack on tough head & neck cancers

Disease control Not yet recruiting

This early-stage trial is testing whether a new drug called camonsertib, combined with a precise form of radiation therapy, can help control head and neck cancers that have returned or cannot be surgically removed. The main goals are to find the safest dose of the drug-radiation …

Matched conditions: UNRESECTABLE HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 30, 2026 14:28 UTC

UNRESECTABLE HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA

Get alerted when new UNRESECTABLE HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA trials appear

New combo attack on tough head & neck cancers